Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma

Journal of Neuro-Oncology

Volumn 122, Issue 1, 2015, Pages 135-143

  Ney, Douglas E ^a   Carlson, Julie A ^a   Damek, Denise M ^a   Gaspar, Laurie E ^a   Kavanagh, Brian D ^a   Kleinschmidt DeMasters, B K ^a   Waziri, Allen E ^a,b   Lillehei, Kevin O ^a   Reddy, Krishna ^a,c   Chen, Changhu ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Inova Medical Group   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Bevacizumab; Glioblastoma; Hypofractionated radiation therapy; Temozolomide

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUTOPSY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED INTENSITY MODULATED RADIATION THERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION NECROSIS; SEIZURE; SEPSIS; THROMBOCYTOPENIA; WOUND DEHISCENCE; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RADIATION DOSE FRACTIONATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84925535339     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1691-z     Document Type: Article

References (29)

1. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
3. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850
4. Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622
5. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer Cell 8:89–91
6. Semenza GL (2004) Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5:405–406
7. Wachsberger PR, Burd R, Cardi C et al (2007) VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 67:1526–1537
8. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005(307):58–62
9. Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99–110
10. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003(3):721–732
11. Crane CH, Eng C, Feig BW et al (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76:824–830
12. Das P, Eng C, Rodriguez-Bigas MA et al (2014) Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 88:301–305
13. Morganti AG, Mignogna S, Caravatta L et al (2014) FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I–II study. J Chemother 26:353–358
14. Schefter T, Winter K, Kwon JS et al (2014) RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 88:101–105
15. Reddy K, Damek D, Gaspar LE et al (2012) Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84:655–660
16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
17. Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588
18. Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91:95–100
19. Floyd NS, Woo SY, Teh BS et al (2004) Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 58:721–726
20. Sultanem K, Patrocinio H, Lambert C et al (2004) The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 58:247–252
21. Chen C, Damek D, Gaspar LE et al (2011) Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81:1066–1074
22. Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C (2011) Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys 81:211–217
23. Omuro A, Beal K, Gutin P, Karimi S et al (2014) Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 20:5023–5031
24. Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495
25. Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317–1324
26. Jeyaretna DS, Curry WT Jr, Batchelor TT et al (2011) Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 29:e159–e162
27. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722
28. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) Randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
29. Peca C, Pacelli R, Elefante A et al (2009) Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 111:331–334